相关临床试验
174
145 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
144
82.8%
已完成
23
13.2%
尚未招募
1
0.6%
招募中
1
0.6%
终止
5
2.9%
暂无批准数据
- The EMA's CHMP adopted a positive opinion recommending KEYTRUDA plus Padcev as neoadjuvant and adjuvant treatment for adults with resectable muscle-invasive bladder cancer. - The recommendation is based on the Phase 3 KEYNOTE-B15 trial, which reduced event-free survival events by 47% versus neoadjuvant chemotherapy and surgery. - KEYNOTE-B15 also showed a 35% reduction in risk of death and a pathologic complete response rate of 55.8% versus 32.5% with chemotherapy. - The European Commission will review the opinion, with a final decision on marketing authorization in the EU expected by the fourth quarter of 2026.
- Inflammasome Therapeutics' dual inflammasome inhibitor K8 reduced geographic atrophy lesion growth by 54% versus control over six months in a Phase 2 trial (p=0.016). - A prespecified extrafoveal analysis showed a 4.0-letter mean BCVA advantage for K8-treated eyes versus controls (p=0.004), a functional endpoint neither approved GA therapy has met. - K8 is delivered as a bioerodible sustained-release intravitreal implant dosed once every three months, potentially reducing treatment burden compared to monthly approved therapies. - No drug-related serious adverse events, endophthalmitis, intraocular inflammation, or neovascular AMD were reported through six months in the 30-patient, 60-eye multicenter trial.
- Physiomics Director Ian Bagnall acquired 1,111,111 ordinary shares at 0.45p per share through market purchases on 14 July 2026. - The transaction brings Mr Bagnall's total holding to 16,111,111 ordinary shares, representing approximately 3.55% of the company's issued share capital. - Physiomics is a mathematical modelling and data science company supporting drug development, with clients including Merck KGaA, Astellas, and Bicycle Therapeutics. - The company's proprietary Virtual Tumour technology has informed the development of over 140 commercial projects across more than 125 targets and drugs.
- Japan ranks among the top global pharmaceutical markets and leads in basic life sciences, yet its domestic biotech startup sector lags far behind the US and China, with only 679 biomedical startups as of June 2025. - Japanese venture capital investment in biotech reached just $913 million in 2023, approximately 3% of US levels, severely limiting the ability of startups to advance clinical pipelines. - Large pharmaceutical companies like Takeda and Astellas dominate talent and innovation, while the lifetime employment system and conservative capital markets stifle entrepreneurial risk-taking. - Government reforms including the Startup Development Five-Year Plan and Bio Policy Action Plan aim to redirect resources toward startups, but bridging the ecological gap will require long-term cultivation.
- General Proximity, a San Francisco biotech company, received investment from FreeMind Investments and Daewoong Pharmaceutical for its innovative induced proximity medicine platform. - The company's proprietary OmniTAC platform scans the "effectome" to identify effector proteins that can modulate previously undruggable disease-causing targets. - General Proximity has secured over $20 million in funding, five "Golden Ticket" awards from major pharma companies, and a strategic collaboration with Daiichi Sankyo. - The investment reflects Daewoong Pharmaceutical's strategic interest in exploring future collaboration opportunities with General Proximity's platform technology.
- TippingPoint Biosciences closed an oversubscribed $4.5 million seed financing led by SOSV and LKS Fund to advance a breakthrough drug discovery platform targeting previously "undruggable" epigenetic protein interfaces. - The company's novel approach recreates disease-specific chromatin environments to reveal transient protein-protein interfaces unique to pathological states, addressing limitations of current epigenetic therapies that often disrupt healthy cell functions. - TippingPoint will focus its lead program on Diffuse Intrinsic Pontine Glioma (DIPG), one of the deadliest childhood cancers driven by chromatin biology disruptions. - The platform represents a fundamentally different strategy from traditional epigenetic enzyme targeting, potentially unlocking broader classes of previously inaccessible targets across cancer and other chromatin dysfunction diseases.
- The Phase III PEACE-3 trial demonstrated that XOFIGO (radium-223 dichloride) combined with enzalutamide reduced the risk of death by 24% compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer and bone metastases. - Patients receiving the combination therapy achieved a median overall survival of 38.2 months versus 32.6 months with enzalutamide monotherapy, representing a 5.6-month improvement. - The combination treatment showed increased serious adverse events (69% vs 58% Grade 3 or higher), though no individual severe adverse event increased by more than 5% compared to enzalutamide alone. - These results build on the primary analysis showing significant improvement in radiological progression-free survival (19.4 vs 16.4 months) with the combination versus enzalutamide alone.
- AstraZeneca's sonesitatug vedotin is set to report pivotal phase 3 data in the first half of 2026 from the global Clarity-Gastric01 trial, testing the ADC in second-line gastric cancer patients with ≥25% Claudin18.2 expression. - Two new phase 3 studies are launching in March 2025, including LaNova's tecotabart vedotin in first-line gastric cancer and FutureGen's FG-M108 monoclonal antibody in first-line pancreatic cancer. - Eight Claudin18.2-targeting ADCs are currently in phase 3 development, with companies seeking to expand beyond Astellas's Vyloy, which is only approved for patients with ≥75% Claudin18.2 expression. - Several Western pharmaceutical companies including Bristol Myers Squibb and Merck & Co have abandoned their Claudin18.2 programs, leaving the field increasingly dominated by Chinese developers.
- The global Claudin 18.2 targeted therapy market is projected to exceed $800 million by 2030, driven by significant opportunities in treating advanced gastric and pancreatic cancers. - Currently one approved therapy exists with over 70 Claudin 18.2 targeted therapies in clinical trials across various development stages, spanning monoclonal antibodies, bispecific antibodies, and CAR-T cell therapies. - Astellas' zolbetuximab (Vyloy) leads the field as the first approved Claudin 18.2 targeted therapy, showing promising results in advanced gastric cancer treatment. - Future expansion is expected beyond gastric cancer into pancreatic, colorectal, and esophageal cancers, with personalized medicine approaches based on individual genetic profiles.
- DeepSeq.AI announced an investment from Zaka VC, alongside funding from Illumina Ventures and biotech family offices, to scale its AI-based protein drug discovery platform. - The company's proprietary LLM-based technology generates and analyzes large experimental datasets for protein drug discovery, including large-scale protein-protein interaction data. - DeepSeq's platform is already commercially available and used by major pharmaceutical companies, with validation through DARPA-funded initiatives. - The funding will be used to scale DeepSeq's datasets and development teams to meet growing demand for collaborations in protein drug discovery.
